Pharma back in focus for CLOs after Trump comments
The pharmaceuticals industry is back under the microscope of US CLO players after comments on drug pricing from president-elect Donald Trump hinted at a tougher environment for drug makers under a Trump presidency.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: